The Impact of COVID-19 is included in Epigenetic Drug and Diagnostic Technology Market Report. Buy it today to get an advantage.
Request the impact of COVID-19 on your product or industry
Epigenetic Drug and Diagnostic Technology Trends and Forecast
The future of the global epigenetic drug and diagnostic technology market looks promising with opportunities in the oncology and non-oncology markets. The global epigenetic drug and diagnostic technology market is expected to reach an estimated $27.7 billion by 2030 with a CAGR of 19.2% from 2024 to 2030. The major drivers for this market are rising prevalence of chronic diseases like cancer and neurological disorders, surge in geriatric population, and innovations of new epigenetic drugs and diagnostics technologies.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Epigenetic Drug and Diagnostic Technology by Segment
The study includes a forecast for the global epigenetic drug and diagnostic technology by type of therapy, technology, application, and region.
Epigenetic Drug and Diagnostic Technology Market by Type of Therapy [Shipment Analysis by Value from 2018 to 2030]:
• HDAC
• DNMT
Epigenetic Drug and Diagnostic Technology Market by Technology [Shipment Analysis by Value from 2018 to 2030]:
• DNA Methylation
• Histone Methylation
• Histone Acetylation
• Large Noncoding RNA
• Microrna Modification
• Chromatin Structures
Epigenetic Drug and Diagnostic Technology Market by Application [Shipment Analysis by Value from 2018 to 2030]:
• Oncology
• Non-Oncology
Epigenetic Drug and Diagnostic Technology Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Epigenetic Drug and Diagnostic Technology Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies epigenetic drug and diagnostic technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the epigenetic drug and diagnostic technology companies profiled in this report include-
• Roche Diagnostics
• Thermo Fisher Scientific
• Eisai
• Novartis
• Illumina
• Merck Sharp & Dohme
• Qiagen
Epigenetic Drug and Diagnostic Technology Market Insights
Lucintel forecasts that DNMT will remain the larger segment over the forecast period due to wide-scale availability.
Within this market, oncology will remain the larger segment due to high growth of cancer and rising number of deaths caused by cancer.
North America will remain the largest region over the forecast period due to presence of well established healthcare facilities and surge in geriatric population in the region.
Features of the Global Epigenetic Drug and Diagnostic Technology Market
Market Size Estimates: Epigenetic drug and diagnostic technology market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Epigenetic drug and diagnostic technology market size by type of therapy, technology, application, and region in terms of value ($B).
Regional Analysis: Epigenetic drug and diagnostic technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type of therapy, technologies, applications, and regions for the epigenetic drug and diagnostic technology market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the epigenetic drug and diagnostic technology market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the epigenetic drug and diagnostic technology market size?
Answer: The global epigenetic drug and diagnostic technology market is expected to reach an estimated $27.7 billion by 2030.
Q2. What is the growth forecast for epigenetic drug and diagnostic technology market?
Answer: The global epigenetic drug and diagnostic technology market is expected to grow with a CAGR of 19.2% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the epigenetic drug and diagnostic technology market?
Answer: The major drivers for this market are rising prevalence of chronic diseases like cancer and neurological disorders, surge in geriatric population, and innovations of new epigenetic drugs and diagnostics technologies.
Q4. What are the major segments for epigenetic drug and diagnostic technology market?
Answer: The future of the epigenetic drug and diagnostic technology market looks promising with opportunities in the oncology and non-oncology markets.
Q5. Who are the key epigenetic drug and diagnostic technology market companies?
Answer: Some of the key epigenetic drug and diagnostic technology companies are as follows:
• Roche Diagnostics
• Thermo Fisher Scientific
• Eisai
• Novartis
• Illumina
• Merck Sharp & Dohme
• Qiagen
Q6. Which epigenetic drug and diagnostic technology market segment will be the largest in future?
Answer: Lucintel forecasts that DNMT will remain the larger segment over the forecast period due to wide-scale availability.
Q7. In epigenetic drug and diagnostic technology market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to presence of well established healthcare facilities and surge in geriatric population in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the epigenetic drug and diagnostic technology market by type of therapy (HDAC and DNMT), technology (DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microrna modification, and chromatin structures), application (oncology and non-oncology), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Epigenetic Drug And Diagnostic Technology Market, Epigenetic Drug And Diagnostic Technology Market Size, Epigenetic Drug And Diagnostic Technology Market Growth, Epigenetic Drug And Diagnostic Technology Market Analysis, Epigenetic Drug And Diagnostic Technology Market Report, Epigenetic Drug And Diagnostic Technology Market Share, Epigenetic Drug And Diagnostic Technology Market Trends, Epigenetic Drug And Diagnostic Technology Market Forecast, Epigenetic Drug And Diagnostic Technology Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents
1. Executive Summary
2. Global Epigenetic Drug and Diagnostic Technology Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Epigenetic Drug and Diagnostic Technology Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Epigenetic Drug and Diagnostic Technology Market by Type of Therapy
3.3.1: HDAC
3.3.2: DNMT
3.4: Global Epigenetic Drug and Diagnostic Technology Market by Technology
3.4.1: DNA Methylation
3.4.2: Histone Methylation
3.4.3: Histone Acetylation
3.4.4: Large Noncoding RNA
3.4.5: Microrna Modification
3.4.6: Chromatin Structures
3.5: Global Epigenetic Drug and Diagnostic Technology Market by Application
3.5.1: Oncology
3.5.2: Non-oncology
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Epigenetic Drug and Diagnostic Technology Market by Region
4.2: North American Epigenetic Drug and Diagnostic Technology Market
4.2.2: North American Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
4.3: European Epigenetic Drug and Diagnostic Technology Market
4.3.1: European Epigenetic Drug and Diagnostic Technology Market by Type of Therapy: HDAC and DNMT
4.3.2: European Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
4.4: APAC Epigenetic Drug and Diagnostic Technology Market
4.4.1: APAC Epigenetic Drug and Diagnostic Technology Market by Type of Therapy: HDAC and DNMT
4.4.2: APAC Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
4.5: ROW Epigenetic Drug and Diagnostic Technology Market
4.5.1: ROW Epigenetic Drug and Diagnostic Technology Market by Type of Therapy: HDAC and DNMT
4.5.2: ROW Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Type of Therapy
6.1.2: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Technology
6.1.3: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Application
6.1.4: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Region
6.2: Emerging Trends in the Global Epigenetic Drug and Diagnostic Technology Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Epigenetic Drug and Diagnostic Technology Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Epigenetic Drug and Diagnostic Technology Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Roche Diagnostics
7.2: Thermo Fisher Scientific
7.3: Eisai
7.4: Novartis
7.5: Illumina
7.6: Merck Sharp & Dohme
7.7: Qiagen
.
Buy full report or by chapter as follows
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Please sign in below to get report brochure - Epigenetic Drug and Diagnostic Technology Market Report.